NL-OMON37659已完成不适用
The Evening vs Morning Polypill Utilization Study - TEMPUS
niversitair Medisch Centrum Utrecht0 个研究点目标入组 75 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Adults (>= 18 years) with:
- •- (A) established atherothrombotic cardiovascular disease (CVD)- history of ischaemic heart disease, ischaemic stroke or transient ischaemic attack, or peripheral vascular disease.
- •- (B) a 5 year cardiocvascular risk of at least 10% (Framingham risk equation, New Zealand Guidelines Group approach).;- The trial investigator and the specialist from the department of Vascular Medicine considers that the polypill components are indicated according to current guidelines at the doses in the Red Heart Pill 2c.
排除标准
- •Individuals will NOT be eligible if one or more of the following criteria are satisfied:
- •Contraindication to any of the components of the polypill (e.g. known intolerance to aspirin, statins, or ACE inhibitors; pregnancy or likely to become pregnant or breastfeeding women during the treatment period). Such contrindications are fully listed in the Investigator Brochure.
- •The treating doctor or trial doctor considers that changing a participant*s cardiovascular medications would put the participant at risk (e.g. symptomatic heart failure, high dose β-blocker required to manage angina or for rate control in atrial fibrillation, accelerated hypertension, severe renal insufficiency, a history of severe resistant hypertension).;Other potential reasons for exclusion include:
- •Known situation where medication regimen might be altered for a significant length of time, e.g. current acute cardiovascular event(s), planned coronary bypass graft operation.
- •Unlikely to complete the trial (e.g. life-threatening condition other than cardiovascular disease) or adhere to the trial procedures or attend study visits (e.g. major psychiatric condition, dementia).
- •Women of child bearing potential should be on a medically accepted form of contraception (oral or implanted contraception, IUD or tubal sterilisation). If there is any possibility of pregnancy, prior to randomisation a blood or urine pregnancy test will be performed. Final decisions about eligibility will be made at the discretion of the trial Investigator and potential trial participant, in light of any additional requirements or guidance from local ethics committees and other regulatory bodies.
- •Night shift worker
研究者
相似试验
撤回
不适用
TEMPUS - The Evening vs Morning Polypill Utilization Study;A randomised controlled cross-over trial to evaluate evening versus morning administration of a cardiovascular polypillcardovascular diseasedyslipidemia100110821000796310003216hypertensionNL-OMON35965niversitair Medisch Centrum Utrecht75
进行中（未招募）
不适用
Effects of morning vs evening dosing on the pharmacokinetics and pharmacodynamics of sunitinib.Renal Cell Cancer, GIST, pancreatic neuroendocrine tumorMedDRA version: 14.1Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10023400Term: Kidney cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10055008Term: Gastric sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000425-45-NL18
招募中
3 期
Effect of Time-of-Day Administration of Amilodipine/Valsartan on Hypertention ControlIRCT20240131060872N1Shahid Beheshti University of Medical Sciences100
已完成
1 期
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male ParticipantsHealthyNCT03405441Janssen Research & Development, LLC42
已完成
3 期
A trial comparing effect of two different regimes of iron supplementation on markers of oxidative stress and anti-oxidant status in children with iron deficiency anemiaCTRI/2010/091/001102il72